CHADDS FORD, PA--(Marketwire - April 10, 2008) - Endo Pharmaceuticals Holdings Inc. (NASDAQ: ENDP) today announced the pricing of its offering of $345 million aggregate principal amount of 1.75% convertible senior subordinated notes due 2015 to qualified institutional buyers in accordance with Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). In addition, Endo announced that the initial purchasers have exercised in full their option to purchase up to an additional $34.5 million in aggregate principal amount of notes to cover overallotments, resulting in the sale of $379.5 million total aggregate principal amount of notes in the offering. The coupon on the notes will be 1.75% per year on the principal amount from April 15, 2008, payable semi-annually in arrears.
